Doran, W. ., Tunnicliffe, L. ., Muzambi, R. ., Rentsch, C. T., Bhaskaran, K. ., Smeeth, L. ., … Warren-Gash, C. . (2024). Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records. BMJ Open Diabetes Res Care, 12. http://doi.org/10.1136/bmjdrc-2023-003548
*Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology
Morgan, C. L., Durand, A. ., McCormack, T. ., Hughes, E. ., Berni, T. R., & Lahoz, R. . (2023). Risk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the CPRD. BMJ Open, 13, e064541. http://doi.org/10.1136/bmjopen-2022-064541
Jeffery, A. ., Bhanu, C. ., Walters, K. ., Wong, I. C., Osborn, D. ., & Hayes, J. F. (2023). Polypharmacy and antidepressant acceptability in comorbid depression and type 2 diabetes: a cohort study using UK primary care data. Br J Gen Pract, 73, e392-e398. http://doi.org/10.3399/bjgp.2022.0295
Cook, S. ., Schmedt, N. ., Broughton, J. ., Kalra, P. A., Tomlinson, L. A., & Quint, J. K. (2023). Characterising the burden of chronic kidney disease among people with type 2 diabetes in England: a cohort study using the Clinical Practice Research Datalink. BMJ Open, 13, e065927. http://doi.org/10.1136/bmjopen-2022-065927
Birkeland, K. I., Bodegard, J. ., Banerjee, A. ., Kim, D. J., Norhammar, A. ., Eriksson, J. W., … Kadowaki, T. . (2021). Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab, 23, 75–85. http://doi.org/10.1111/dom.14189